Lidong is a lactulose oral solution product launched by Beijing Hanmei in 2006. Beijing Hanmei Pharmaceutical Co., Ltd. (hereinafter referred to as Beijing Hanmei) was established in March 1996 and is located in the beautiful environment of Beijing Shunyi Airport Development Zone, covering an area of ​​13,600 square meters.

In addition to its headquarters, Beijing Hanmei also has a research center, a GMP factory and a sales team all over the country. In 2008, it established a "Business Center" with international advanced level, integrating "research and development, production and sales". Three are in one. Among them, the GMP factory was carefully designed and built strictly in accordance with the GMP standards. It passed the GMP certification of the State Administration of Drug Administration in December 2001 and officially put into production and use, and passed the new version of the GMP certification at the end of 2015. The research center has an area of ​​nearly 4,000 square meters, including biological laboratories, chemical synthesis laboratories and pharmacological toxicology laboratories. It is equipped with a variety of world-class drug research equipment, and is equipped with advanced foreign research and development centers, Korean and American pharmaceutical headquarters, Korean and American fines Chemical plants and formula R&D centers work closely together to form an advanced and high-end global R&D network. The sales team covers all provinces, autonomous regions, municipalities directly under the central government and hundreds of cities and counties in China.

The company's product business involves pediatric products, gastroenterology products, orthopedic products, anti-infective drugs and other fields. 98% of the products are produced in China. The main products include Mommy Ai, Yi Tanjing, Mei Changan, Li Dong, and Aceclofenac. More than a dozen varieties, including Ruimai, etc. Among them, Mommy Ai and Yi Tanjing have become basic regular medicines for children in China and are very popular among doctors and children's parents.

For the precious life of mankind, Beijing, South Korea and the United States want to produce better medicines. In order to realize the common ideal, Beijing, South Korea and the United States will strive for it. For social progress and personal progress, Beijing, South Korea and the United States will do their best to do their best. In the future, Beijing, South Korea and the United States will be committed to producing more high-quality and high-tech drugs and contribute to the country's medical industry.